Catheter Precision (VTAK) AI Stock Analysis

• Market Cap: $4.60M
• Dividend Yield: N/A
• Average Volume (3M): 28.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 9.57%
• EPS Growth: 10.03%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 12,593,873
• 10 Day Avg. Volume: 81,336,406
• 30 Day Avg. Volume: 28,013,770
• PEG Ratio: N/A
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.28
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 2.26
• Enterprise Value/Gross Profit: 9.07
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $0.50 ▲(38.89%Upside)

The most significant factors impacting the score are the financial performance challenges and valuation concerns. While there is positive technical momentum and promising product sales, the risks associated with leadership changes and stock dilution weigh heavily on the overall outlook.

Catheter Precision Business Overview & Revenue Model

Company Description

Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.

How the Company Makes Money

Catheter Precision generates revenue primarily through the sale of its catheter-based medical devices to hospitals, clinics, and healthcare providers. The company may also engage in strategic partnerships with larger medical device firms to expand its market reach and distribution capabilities. Additionally, revenue streams could include licensing agreements for its proprietary technology and intellectual property, as well as potential service agreements for training and support related to the use of its products. The company’s earnings are influenced by factors such as the adoption rate of its technologies in healthcare facilities, the development of new products, and its ability to navigate regulatory approvals in various markets.

Catheter Precision Financial Statement Overview

Summary

VTAK's financial performance is weak, with significant challenges in profitability and cash flow. The income statement highlights declining revenue and operational losses. The balance sheet shows some financial stability due to equity financing, but ongoing negative cash flows and net losses are concerning.

Income Statement

The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.

Balance Sheet

The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.

Cash Flow

Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
481.00K	420.00K	442.00K	14.00K	22.00K	4.41M
	Gross Profit
433.00K	378.00K	412.00K	-147.00K	-1.54M	-1.08M
	EBIT
-12.19M	-11.24M	-78.12M	-26.96M	-29.27M	-36.06M
	EBITDA
-11.23M	-11.30M	-15.11M	-22.37M	-27.70M	-33.30M
	Net Income Common Stockholders
-18.01M	-16.64M	-70.57M	-26.86M	-25.07M	-36.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.22M	2.87M	3.56M	15.86M	15.04M	23.91M
	Total Assets
48.51M	27.77M	30.74M	16.84M	21.04M	33.44M
	Total Debt
139.00K	1.79M	372.00K	124.17K	2.26M	4.88M
	Net Debt
-12.08M	-1.08M	-3.19M	-15.73M	-12.78M	-19.02M
	Total Liabilities
12.65M	16.01M	9.54M	7.58M	7.37M	12.29M
	Stockholders Equity
35.86M	11.76M	21.19M	9.26M	13.67M	21.15M
Cash Flow		Free Cash Flow
-9.72M	-9.34M	-20.70M	-22.59M	-27.89M	-28.37M
	Operating Cash Flow
-9.67M	-9.27M	-20.62M	-22.57M	-27.63M	-28.30M
	Investing Cash Flow
-55.00K	-67.00K	-61.00K	21.00K	3.80M	15.93M
	Financing Cash Flow
8.68M	8.65M	8.39M	23.36M	14.96M	21.69M

Catheter Precision Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.28, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 55.93 is Neutral, neither overbought nor oversold. The STOCH value of 44.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTAK.

Catheter Precision Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSCS	54 Neutral	$3.89M	―	-163.47%	―	-100.00%	78.91%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
VTAK	49 Neutral	$4.60M	―	-136.26%	―	9.57%	10.03%
VVOS	46 Neutral	$12.60M	―	-450.47%	―	9.47%	81.37%
NUWE	45 Neutral	$1.33M	―	-440.77%	―	-1.21%	93.72%
SINT	42 Neutral	$8.20M	―	-155.20%	―	9.90%	94.56%
RSLS	37 Underperform	$6.01M	―	-120.16%	―	-7.74%	93.25%

Catheter Precision Corporate Events

Catheter Precision’s LockeT Sales Surge in Q2 2025

Catheter Precision announced that its LockeT product sales for Q2 2025 are on track to be the highest to date, surpassing Q2 2024 sales by over $84,000. The company has secured a new distributor in Italy and is seeking additional distributors in Spain, Portugal, and the UK, aiming to expand its European footprint. Three U.S. hospitals are expected to issue significant purchase orders for LockeT by the end of 2025, indicating strong market interest. The CE Mark approval for LockeT facilitates its sales in Europe, and a live demonstration is scheduled in Italy to boost product awareness.

Catheter Precision Approves Warrant Issuance to Ladenburg

On June 5, 2025, Catheter Precision, Inc.’s Board of Directors approved a warrant issuance to Ladenburg Thalmann & Co., Inc. as partial compensation for services related to the company’s pipe financing closed on May 12, 2025. This warrant allows the purchase of 257,143 shares at $0.5424 per share, pending stockholder approval at the annual meeting on July 25, 2025. The warrant will expire on June 6, 2030, and neither it nor the underlying shares have been registered under the Securities Act of 1933.

Catheter Precision Announces CCO Departure and Leadership Change

On June 2, 2025, Catheter Precision, Inc. announced the discontinuation of employment for their Chief Commercial Officer, Marie-Claude Jacques. Executive Chairman and CEO David Jenkins will temporarily assume the role until a new replacement is found, which may impact the company’s commercial operations and leadership dynamics.

Catheter Precision Announces New Common Stock Offering

Catheter Precision has announced a new offering of common stock that will result in dilution for new investors. As of March 31, 2025, the net tangible book value per share was $(1.71), and after adjustments, it is expected to be $(0.95) per share. This represents an immediate increase in value for existing shareholders but a substantial dilution for new investors purchasing at the assumed offering price of $0.30 per share. The company may also raise additional capital, which could lead to further dilution.

Catheter Precision Enters Market Offering Agreement

On May 19, 2025, Catheter Precision, Inc. entered into an At Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to potentially sell up to $1.3 million of its common stock. The proceeds from any sales will be used to fund operations and working capital. Ladenburg will sell shares based on the company’s instructions, adhering to legal and exchange rules. The agreement can be terminated by either party with notice, and Ladenburg will receive a 3% commission on sales.

Catheter Precision Enters Securities Purchase Agreement

On May 12, 2025, Catheter Precision, Inc. entered into a Securities Purchase Agreement with three investors, selling 1.5 million shares of its Series B Convertible Preferred Stock and issuing an additional 1.5 million shares as consideration for existing senior secured Convertible Promissory Notes of QHSLab, Inc. The company has reserved up to 8,574,000 shares of common stock for conversion and issued Series L warrants for purchasing up to 4,285,716 shares of common stock. The conversion and exercise of these securities are subject to stockholder approval, which the company plans to seek at its Annual Meeting on July 25, 2025. The Series B Convertible Preferred Stock has a fixed conversion price of $0.35 per share, while the Series L warrants have a 5 ½ year term and are exercisable at $0.50 per share. The securities offering was conducted under an exemption from registration requirements, and the company intends to register the shares for resale by May 27, 2025.

Catheter Precision Finalizes Strategic Cardiac Acquisition

In February 2025, Catheter Precision, Inc. formed a subsidiary, Cardionomix, Inc., to acquire assets from Cardionomic, Inc., which had ceased operations. On April 18, 2025, Cardionomix entered into an agreement to purchase assets related to a late-stage treatment for acute decompensated heart failure, including patents and trademarks for the Cardiac Pulmonary Nerve Simulation System. The acquisition was finalized on May 5, 2025, with Catheter Precision issuing 1,000,000 restricted shares and Cardionomix providing a $1.5 million promissory note. This strategic acquisition aims to enhance Catheter Precision’s portfolio in cardiac care, although it involves financial obligations and potential equity dilution for stakeholders.